CD276
ENSG00000103855
Target class
Surface antigen
Chromosome
15
Approved drugs
0
Clinical candidates (approved and in development)
2
- Approved drugs
- 0
- Clinical candidates (approved and in development)
- 2
- Chemical probe available
- No
- Target name
- CD276
- Gene name
- CD276 molecule
- Gene symbol
- CD276
- Protein name
- CD276 antigen (4Ig-B7-H3) (B7 homolog 3) (B7-H3) (Costimulatory molecule) (CD antigen CD276)
- B7-H3
- B7H3
- B7RP-2
- Gene biotype
- Protein coding
- Gene family
- CD molecules|V-set domain containing|C2-set domain containing|B7 family
- Target class
- Surface antigen
- Target type
- Human gene
- Tissues expressed in
- 53
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 63.18
- Tissue specificity (Gini)
- 0.416
- Tissue specificity (tau)
- 0.708
- KEGG gene identifiers
- hsa:80381
- Protein interaction confidence
- 0.817848
- Protein interaction partners
- 33
- End position
- 73714518
- Start position
- 73683966
- Chromosome
- 15
- Strand
- Forward
- Membrane
- Single-pass type I membrane protein .
- Vesicles
- Tissue specificity (tau)
- 0.70772
- Expression inequality (Gini)
- 0.416113
Expression in transcripts per million
- Cells - Cultured fibroblasts
- 63.18
- Cervix - Ectocervix
- 54.04
- Cervix - Endocervix
- 51.38
- Adipose - Subcutaneous
- 46.66
- Artery - Aorta
- 41.78
Expression in transcripts per million
- Cells - Cultured fibroblasts63.18
- Cervix - Ectocervix54.04
- Cervix - Endocervix51.38
- Adipose - Subcutaneous46.66
- Artery - Aorta41.78
- Artery - Tibial39.69
- Uterus35.64
- Prostate34.15
- Artery - Coronary32.28
- Adrenal Gland32.04
- Ovary30.88
- Bladder30.83
- Skin - Sun Exposed (Lower leg)30.11
- Breast - Mammary Tissue29.85
- Vagina29.14
- Nerve - Tibial26.29
- Lung25.17
- Minor Salivary Gland24.79
- Colon - Sigmoid23.16
- Thyroid22.2
- Skin - Not Sun Exposed (Suprapubic)21.96
- Adipose - Visceral (Omentum)21.73
- Fallopian Tube21.42
- Esophagus - Gastroesophageal Junction19.33
- Esophagus - Muscularis18.29
And 29 more, listed on the interactive page.
- GO:0032729
- GO:0042102
- GO:0042110
Molecular functions
- GO:0005515
Related records
Trials (28)
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
- A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)
- A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
- A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
- A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
- A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
- A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
- A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
- Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors
- Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck
- Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer
- FT516 and IL2 With Enoblituzumab for Ovarian Cancer
- Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
- Intraperitoneal RIT With 131I-8H9 for Pts With DSRCT and Other Solid Tumors Involving the Peritoneum
- KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
- Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer
- MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
- Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer
Drugs (3)
- 8H9 131I CD276 antigen binding agent
- Enoblituzumab CD276 antigen cross-linking agent
- Ifinatamab deruxtecan